Antibodies - 5 News by Micromet for the pharma industry

Antibodies - 5 News by Micromet for the pharma industry

Micromet Initiates Phase 2 Trial of Blinatumomab in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

22-Sep-2010 - Micromet, Inc. announced the initiation of a phase 2 trial of the Company’s lead product candidate blinatumomab (MT103) in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL). Blinatumomab is the first of a new class of agents called BiTE® antibodies, ...

antibodies acute lymphoblastic leukemia chemotherapy

Micromet's Blinatumomab Induces Durable Remissions in Patients with Relapsed Non- Hodgkin's Lymphoma

16-Jun-2010 - Micromet, Inc. announced the presentation of updated results from a Phase 1 trial of the Company's lead product candidate blinatumomab (MT103) in patients with relapsed non-Hodgkin's lymphoma (NHL). A high objective response rate was maintained among patients treated with blinatumomab using an ...

antibodies chemotherapy dosing

Micromet Buys Out MedImmune’s Remaining Rights to Blinatumomab

10-Nov-2009 - Micromet, Inc. announced that it has signed an agreement with MedImmune, LLC to buy out MedImmune’s rights to blinatumomab in North America, and to terminate the collaboration agreement signed in 2003 under which MedImmune had been granted the right to develop and commericalize blinatumomab in ...

antibodies antigens leukemia

Micromet and Sanofi-aventis Sign Global Collaboration and License Agreement for New Solid Tumor BiTE Antibody

02-Nov-2009 - Micromet, Inc. and sanofi-aventis announced a global collaboration and license agreement to develop a BiTE(R) antibody against an antigen present at the surface of carcinoma cells. BiTE antibodies are novel therapeutic antibodies that activate a patient's T cells to seek out and destroy cancer ...

antibodies therapeutic antibodies clinical trials

Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110

The First BiTE Antibody for Treatment of Solid Tumors

28-Apr-2008 - Micromet, Inc. announced the start of a phase 1 clinical trial with its BiTE® antibody MT110. The study will explore the safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of MT110 in patients with lung and gastrointestinal cancers. MT110 targets the epithelial cell adhesion ...

antibodies adhesion cancer stem cells

These products might interest you

Greener Alternative Products

Greener Alternative Products by Merck Life Science

Sustainable laboratory products for environmentally conscious research

Over 2,500 ecological alternatives to reduce your laboratory footprint

consumables
View product
Antibody Stabilizer

Antibody Stabilizer by CANDOR Bioscience

Protein and antibody stabilisation made easy

Long-term storage without freezing - Simple application, reliable protection

stabilization solutions
View product
LowCross-Buffer®

LowCross-Buffer® by CANDOR Bioscience

Improve Accuracy of Your ELISAs!

LowCross-Buffer for reliable immunoassays.

buffers
View product
Liquid Plate Sealer

Liquid Plate Sealer by CANDOR Bioscience

Protection for Antibodies and Antigens Coated on Plates

For Long-Term Stability of Antibodies Coated on ELISA-Plates, Affinity Columns and Other Surfaces

buffers
View product
Show all antibodies

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Haven't found the right news yet?

The bionity.com news search

Start your targeted search now with a wide range of filter options. Our database includes an archive of 26,479 life science news from business and science, which you can search by topic and organization, filtered by time and geography.

Start news search now